Clinical trial · Interventional
L-carnosine Prophylactic Effect on Oxaliplatin Induced Peripheral Neuropathy in GIT Cancer Patients
The Potential Prophylactic Effect of Exogenous Antioxidant ''L-CARNOSINE'' on Oxaliplatin-induced Peripheral Neuropathy in Cancer Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study evaluates the prophylactic effect of exogenous L-CARNOSINE in Oxaliplatin induced peripheral neuropathy, Thus half of the patients will receive L-CARNOSINE with Oxaliplatin and the other half will not receive L-CARNOSINE with their chemotherapy (oxaliplatin),And then neuropathy together with some oxidative stress markers will be assessed at the end of treatment duration (three months) .
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Peripheral Neuropathy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| L-CARNOSINE | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Treatment group
- description
- this arm will receive L-CARNOSINE PO (each patient will receive 1 tablet daily and each tablet contains 500 mg thus a total of 500 mg per day) together with their chemotherapy wich is oxaliplatin.
- interventionNames
- Drug: L-CARNOSINE
- type
- NO_INTERVENTION
- label
- Control group
- description
- This arm wont receive L-CARNOSINE, they will receive their chemotherapy (oxaliplatin) only.
Primary outcomes (1)
- measure
- Assessment of peripheral neuropathy using neuropathy grading score "CTCAE", version 4.0) also oxidative stress markers will be measured by ELISA kits.
- timeFrame
- Three months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: Patients are eligible to be enrolled in this study, if they meet the following criteria 1. Elderly males and females with age (˃18 and ˂60). 2. Cancer patients treated with oxaliplatin for the first time (dose 85- 135mg/m2) administered every two to three weeks for 3 months. Exclusion Criteria: Excluded from this study are the patients with the following Criteria: * Suffering from diabetes mellitus. * Suffering from peripheral neuropathy as a result of any other disease or drug. * Suffering from severe renal impairment (CrCl ˂ 30 ml/min). * Suffering from epilepsy. * Taking vitamin B. * Who previously took Oxaliplatin or any other chemotherapeutic agent that causes peripheral neuropathy. * Taking antidepressants or MAOI's. * Taking NSAIDs, paracetamol, opiates or any other analgesics or pain killers. * Pregnant or lactating patients.
References
Publications (0)
Data not yet available